Cellular immunotherapy is a popular track that has received more attention recently, but many stockholders don't know what cellular immunotherapy concept stocks are, and today Wealth Management Jun combed through a list of leading cellular immunotherapy stocks for stockholder friends for your reference.
Boten (300363)
Chongqing Boten Pharmaceutical Science and Technology Company Limited's main business is chemical API CDMO, chemical preparation CDMO, biological CDMO business. It is mainly dedicated to providing global pharmaceutical companies, new drug research and development organizations, etc. with custom R&D and custom manufacturing services for chemical APIs, chemical formulations and biological drugs required for the whole life cycle from preclinical to clinical trials until the drugs are launched on the market, including, but not limited to, process route design, development and optimization, analytical method development, process and analytical validation, process safety assessment, quality research, laboratory pilot test, pilot test, commercial production, etc.
New Open Source (300109)
Boai New Open Source (300109) Medical Technology Group Co., Ltd.'s main business includes fine chemicals and precision medicine. The main production products of the fine chemical business are: polyvinylpyrrolidone (PVP) series and related intermediates, vinyl methyl ether/maleic anhydride*** polymers (PVM/MA, Oritz) and related intermediates, oral care related series, etc.. The main products/services of the precision medicine business are: tumor early screening with gene sequencing as the main technology platform, molecular diagnosis of women's diseases, individualized medical services, etc. In September 2009, the company was recognized as a "high-tech enterprise", Certificate No.: GR200941000051, valid for 3 years.
Hengrui Medicine (600276)
Jiangsu Hengrui Medicine (600276) Co., Ltd.'s main business involves the research and development, production and sales of pharmaceuticals, and its main products are Erythroxib Tablets, Apatinib Mesylate Tablets, Thorpexfegestimine Injections, Pyrrolitinib Maleate Tablets, and Karelizumab for Injection, Rimazolam Mesylate for Injection, Fluzoparib Capsules, Heptaparib Ethanolamine Tablets, Iodixanol Injection, Butorphanol Tartrate Injection, Tolvaptan Tablets, Docetaxel Injection, Irbesartan Tablets, and Atracurium Cisbenzenesulfonate for Injection. The company is one of the largest research and production bases of anti-tumor drugs, surgical drugs and contrast agents in China. The company's products cover a wide range of fields such as antitumor drugs, drugs for surgical anesthesia, special infusion, contrast agents, cardiovascular drugs, etc. It has formed a relatively complete product layout, of which the market share in the fields of antitumor, surgical anesthesia, and contrast agents is among the top in the industry. In the National Pharmaceutical Industry Information Annual Conference released "2020 China Pharmaceutical (600056) R & D product line...
Fosun Pharmaceutical (600196)
Shanghai Fosun Pharmaceutical (600196) (Group) Co., Ltd. main business is pharmaceuticals, medical devices and medical diagnostics, medical and health services. The main products are core products in the field of treatment of cardiovascular system diseases, core products in the field of treatment of central nervous system diseases, core products in the field of treatment of blood system diseases, core products in the field of treatment of metabolic and digestive system diseases, core products in the field of treatment of anti-infective diseases, core products in the field of treatment of antitumor, core products in the field of APIs and intermediates. According to the 2018 list of the top 100 enterprises in China's pharmaceutical industry issued by the China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology of the People's Republic of China*** and the State of China, the Group was ranked No. 7; according to the IQVIA statistics, in 2019, the Group ranked No. 10 in the country in terms of sales revenue from the hospital-use prescription drugs manufactured by the Group.As one of the largest enterprises in the world in the production, research and development, and manufacturing of anti-malarial medicines, the Group has become a global fund, United Nations Children's Fund, the World Health Organization and the drug procurement centers of African countries...
Zoli Pharmaceuticals (300181)
Zhejiang Zoli Pharmaceuticals (300181) Co., Ltd.'s main business is the research and development, production and sales of medicinal fungi wuling and bailing series of products, traditional Chinese medicines and Chinese medicine tablets and Chinese medicine formula granules. The Company's main products include Wu Ling series and Bai Ling tablets, Chinese medicine tablets and Chinese medicine formula granules. According to the 2020 Comprehensive Statistical Ranking of OTC Drug Manufacturers and Products in China, the Company's Wuling Capsule ranked No. 3 in the 2020 Comprehensive Statistical Ranking of OTC Drugs (Proprietary Chinese Medicines) "Headache and Insomnia", and the controlling subsidiary, Everest Pharmaceuticals' Bailing Tablets, ranked No. 1 in the 2020 Comprehensive Statistical Ranking of OTC Drugs (Proprietary Chinese Medicines) "Headache and Insomnia". The holding company, Everest Pharmaceuticals, ranked No. 9 in the "Tonic Category" in the 2020 China Over-the-Counter Drugs Comprehensive Statistics Ranking (Proprietary Chinese Medicines).
Nanhua Biological (000504)
Nanhua Biomedical Co., Ltd. is mainly engaged in the business of "biomedicine" and "energy conservation and environmental protection". The company's "biomedical" plate business includes stem cell storage and technical services, stem cell therapy research, etc.; the company's "energy saving and environmental protection" plate business includes external EMC contract energy management business, BT business and sales of related products and sewage treatment. The company's "energy saving and environmental protection" segment includes EMC contract energy management business, BT business and sales of related products, and sewage treatment.
Huahai Pharmaceuticals (600521)
Zhejiang Huahai Pharmaceuticals (600521) Company Limited is a company mainly engaged in the production and sale of raw materials, pharmaceutical intermediates and preparations. The company's main products include Prilosec, Sartan and other high blood pressure APIs. The company is the first enterprise in China to pass the FDA preparation certification, and is in the leading position in the domestic industry in the fields of international GMP certification, overseas registration of preparations as well as APIs, and international cooperation.
*ST Hejia (300273)
Zhuhai Hejia Medical Equipment Co., Ltd. is based on the research and development, manufacturing and sales of medical equipment and consumables, and plans, designs and implements medical professional projects for public hospitals at all levels to create oncology centers, rehabilitation centers, interventional centers and other key clinical disciplines. The company mainly operates minimally invasive tumor treatment equipment, medical molecular sieve oxygen equipment and engineering, conventional diagnostic and therapeutic equipment and medical equipment agent distribution of four business segments. The company has been recognized as a national high-tech enterprises, national intellectual property advantageous enterprises, and approved by the National Bo Management Office set up by the Zhuhai (National) Hengqin New District postdoctoral research station.
Haixin (600851)
Shanghai Haixin Group Co., Ltd.'s main business is the manufacture and sale of pharmaceutical products, the production and sale of plush fabrics and apparel, the park's property leasing and operation, and financial investment. The main products it manufactures cover various industries such as pharmaceuticals, toys, real estate, warehousing and transportation. The company imports Japanese raw materials and engages in research and development of plush fabrics, spinning/yarn processing of polyester and acrylic, and production of plush toys, synthetic fiber blankets, garments and other related textiles, and has developed to the present processing and manufacturing of chemical raw material drugs, biologics, health care products, traditional Chinese medicines raw materials and all kinds of preparations, etc., and also engages in the investment business and asset management which are in line with the national industrial policy.
Zhao Yan New Drugs (603127)
Beijing Zhaoyan New Drugs (603127) Research Center Limited main business focuses on the safety evaluation of the whole life cycle of the drug and monitoring services, the drug preclinical research services for the company's core business, the main content of the drug includes non-clinical safety evaluation services, pharmacodynamics research services, animal and plant research services. Its preclinical research service is the core business of the company, which mainly includes non-clinical safety evaluation service, pharmacodynamics research service, animal pharmacokinetic research service and drug screening. The company is the first professional new drug preclinical safety evaluation organization in China that has passed the FDAGLP inspection in the United States, and has both AAALAC (International Association for the Accreditation of Laboratory Animal Welfare) certification and GLP certification by China CFDA. The test reports and safety data provided have been recognized by the US FDA and other international drug regulatory agencies as well as the China CFDA to support clinical studies in their respective countries.